Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management. Issue 3 (March 2022)

• Record Type: Journal Article
• Authors: Li, Shihai; Xu, Zili; Guo, Mingkun; Li, Menglong; Wen, Zhining
• Is Part Of: Drug discovery today. Volume 27:Issue 3(2022)
• Page Start: 831
• Page End: 837
• Publication Date: 2022-03
• Subjects: Drug-induced prolongation of the QT interval -- Torsades de pointes -- Cardiotoxicity -- Drug safety -- Adverse drug reaction; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2021.10.009
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: A curated drug-induced QT prolongation atlas was developed. A schema was proposed to stratify the risk of drug-induced QT prolongation. Diverse information of QT prolonging drugs was collated in the database. The database can be helpful for investigating the drug-induced torsade de pointes. Abstract: Drug-induced prolongation of the QT interval is common in a variety of pharmaceutical treatments and can lead to serious clinical outcomes. Although substantial efforts have been made to prevent drug-induced QT interval prolongation, the lack of a centralized data source remains the main obstacle to further study of the underlying mechanism and the development of effective prediction strategies. To fill this gap, we propose a schema for stratifying the risk of marketed QT prolonging drugs based on US Food and Drug Administration (FDA)-approved drug labeling and developed a Drug-Induced QT Prolongation Atlas (DIQTA). Potential application of DIQTA was shown by precision dosing in off-label use and therapeutic strategy optimization, as well as the facilitation of artificial intelligence (AI)-based modeling in predictive toxicity.